BioSpace News Archive

Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced an amendment to its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut allergy.

Elucid, a company developing a novel, non-invasive medical software to comprehensively characterize cardiovascular disease, announced the closing of a $27 Million Series B financing round.

In a presentation titled “Reaching the goal with higher speed and confidence”, CEO Dr Werner Lanthaler and CFO Enno Spillner presented Evotec SE’s current strategic, scientific and technological developments, highlights of the 2021 business year and the commitment to sustainability/ESG.

The U.S. Continuous Renal Replacement Therapy Market size was valued at US$ 995.7 million in 2021 and is expected to hit US$ 1.2 Billion by 2030, growing at a compound annual growth rate (CAGR) of 7.9% from 2022 to 2030.

MicroPort Orthopedics, a global leader in orthopedic devices and technologies, today announces that it will be hosting its first annual Global Medial-Pivot Symposium in Chicago from October 13-15, 2022.

LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, conducted a study analyzing the current global lung cancer drug development landscape.

Today, the U.S. Food and Drug Administration is providing an update on the steps it has taken, and will continue to take, to ensure that American consumers have access to safe and nutritious infant formula in the coming weeks and months.

Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the quarter and fiscal year ended April 30, 2022 on June 29, 2022 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time).

Rockwell Medical, Inc. (Nasdaq: RMTI), today provided an update on its recent capital raise and a clinical update on safety enhancements to its planned Phase 2 clinical trial of Ferric Pyrophosphate Citrate (FPC) in home infusion patients.

The Menarini Group and Radius Health, Inc. announced that Menarini, with support from Radius, has submitted a New Drug Application to the U.S. Food and Drug Administration for elacestrant in patients with ER+/HER2- advanced or metastatic breast cancer.